TORONTO, Feb. 7, 2024 /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce receipt of GMP certification for their Barrie, Ontario facility from ANVISA, the governing body of Brazil's pharmaceutical industry. MediPharm Labs now has GMP certification from the United States FDA, European Union, Australia's TGA and holds a drug establishment license from Health Canada.
Read more at newswire.caMediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health Authority
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
